This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Free Online Activities

Clinical Impact of Updated Diagnostic and Research Criteria for Alzheimer’s Disease

Eric M. Reiman, MD; Guy M. McKhann, MD; Marilyn S. Albert, PhD; Reisa A. Sperling, MD; Ronald C. Petersen, MD,PhD; and Deborah Blacker, MD, ScD

Published: December 15, 2011

Article Abstract

Almost 30 years ago, the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (more commonly known as the Alzheimer’s Association) developed the original clinical diagnostic criteria for Alzheimer’s disease (AD). Recently, the National Institute on Aging and the Alzheimer’s Association released updated research and diagnostic criteria for AD. The new criteria establish that AD exists on a continuum and is comprised of not only dementia but also a preclinical phase and a phase of mild cognitive impairment due to AD. The new criteria also describe advancements in biomarker evidence, which is still being researched and is not yet ready for clinical settings. Additionally, the American Psychiatric Association is currently revising the Diagnostic and Statistical Manual of Mental Disorders, which will include updated diagnostic criteria for AD and other neurocognitive disorders.

See the entire activity.


 

Volume: 72

Quick Links: Dementia , Neurologic and Neurocognitive

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...

Read More...